Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;13(2):112-114.
doi: 10.15420/ecr.2018.13.2.EO2.

Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians different from Caucasians?

Doreen Tan Su-Yin  1
Affiliations
Review

Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians different from Caucasians?

Doreen Tan Su-Yin. Eur Cardiol. 2018 Dec.

Abstract

All studies to date involving platelet reactivity and gene testing document singular interventions and their associations with outcomes. The East Asian paradox has been well documented - Asians who have had a percutaneous coronary intervention (PCI) are at a lower risk of ischaemic events even though they have a higher platelet reactivity. Asians who have had a PCI also have a higher risk of bleeding. This article covers the differences in outcomes between Caucasians and Asians, and explores the impact of outcomes, highlighting differences between the two patient populations. Given the high prevalence of loss-of-function alleles in Asia, treatment strategies will differ for different populations. It is plausible that both platelet reactivity and gene testing should be used to inform holistic decision-making for all patients - Caucasian or Asian - with acute coronary syndrome who are undergoing PCI.

Keywords: Asian; CYP2C19 gene testing; Clopidogrel; de-escalation; platelet reactivity testing.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The author has no conflict of interest to declare.

Figures

Figure 1:
Figure 1:. Clopidogrel or Prasugrel Use by CYP2C19 Phenotype Group
See this image and copyright information in PMC

References

    1. WHO. Cardiovascular disease. www.who.int/cardiovascular_diseases Available at: (accessed 13 December 2018)
    1. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57. doi: 10.1056/NEJMoa0904327. - DOI - PubMed
    1. Kang J, Kim HS. The Evolving concept of dual antiplatelet therapy after percutaneous coronary intervention: focus on unique feature of East Asian and ‘Asian Paradox’. Korean Circ J. 2018;48:537–51. doi: 10.4070/kcj.2018.0166. - DOI - PMC - PubMed
    1. Serebruany VL, Dinicolantonio JJ, Can MM et al. Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. Cardiology. 2013;126:35–40. doi: 10.1159/000350961. - DOI - PubMed
    1. Levine GN, Jeong YH, Goto S et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11:597–606. doi: 10.1038/nrcardio.2014.104. - DOI - PubMed